In a patient with suspected drug reaction with eosinophilia and systemic symptoms (DRESS) who is already on brivaracetam, can perampanel be used as a safe alternative antiepileptic drug to replace divalproex, and how does it compare to other non‑aromatic options?

Perampanel as an Alternative AED in Suspected DRESS Syndrome

Perampanel itself can cause DRESS syndrome and should NOT be considered a safe alternative in a patient with suspected DRESS—you must discontinue the culprit drug immediately and avoid introducing another antiepileptic that carries DRESS risk. 1

Critical FDA Warning on Perampanel and DRESS

The FDA label explicitly states that Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including FYCOMPA (perampanel). DRESS may be fatal or life-threatening. The label mandates that perampanel should be discontinued if an alternative etiology for the signs or symptoms cannot be established. 1

This is not theoretical—perampanel carries a black-box-level warning about DRESS in its official prescribing information, making it an inappropriate choice when DRESS is already suspected from another AED.

Understanding the Clinical Context

In your scenario, the patient is suspected of having DRESS from divalproex (valproate). The FDA label for divalproex confirms that DRESS has been reported with valproate therapy and may be fatal or life-threatening. 2 Recent case reports document valproate-induced DRESS with hepatotoxicity and multiorgan involvement. 3, 4

The fundamental principle here is: when DRESS is suspected, you must immediately discontinue the offending agent and avoid cross-reactivity or introducing new drugs with similar DRESS risk. 5

Why Perampanel is NOT the Answer

1. Direct DRESS Risk

• Perampanel is documented to cause DRESS syndrome itself 1
• Introducing a new AED with known DRESS potential during an active or suspected DRESS reaction creates compounded risk
• You cannot distinguish whether ongoing symptoms are from the original culprit or the newly introduced drug

2. Timing Considerations

• Guidelines recommend avoiding skin testing (patch test/intradermal testing) until ≥6 months after acute DRESS reaction and after the patient has been off systemic corticosteroids for ≥1 month 5
• The relapse rate for DRESS is 12% in some studies 5
• Introducing any new potentially cross-reactive or DRESS-associated AED during this vulnerable period is contraindicated

3. The Patient is Already on Brivaracetam

• Brivaracetam is a non-aromatic AED with significantly lower DRESS risk compared to aromatic AEDs (phenytoin, carbamazepine, lamotrigine) or perampanel
• While levetiracetam (structurally related to brivaracetam) has rare DRESS reports 6, 7, brivaracetam represents a safer mechanistic class
• If seizure control is inadequate on brivaracetam alone, consider dose optimization or adding another truly low-risk non-aromatic AED

Safer Alternative AED Options in Suspected DRESS

When DRESS is suspected from divalproex, prioritize:

Non-Aromatic AEDs with Lower DRESS Risk:

• Levetiracetam (though rare DRESS cases exist 6, 7, risk is substantially lower than aromatic AEDs or perampanel)
• Lacosamide (non-aromatic, minimal DRESS association)
• Gabapentin (non-aromatic, minimal DRESS association)
• Pregabalin (non-aromatic, minimal DRESS association)
• Topiramate (though note: can cause hyperammonemia when combined with valproate if valproate hasn't been fully cleared 2)

Avoid These AEDs:

• Aromatic AEDs: Phenytoin, carbamazepine, oxcarbazepine, lamotrigine (high DRESS risk with cross-reactivity) 7, 8, 4, 9
• Perampanel: Direct FDA warning for DRESS 1
• Valproate/divalproex: Already the suspected culprit 2, 7, 3, 4

Clinical Algorithm for AED Selection in Suspected DRESS

1. Immediately discontinue divalproex (suspected culprit)
2. Continue brivaracetam (already on board, non-aromatic, lower risk)
3. If additional seizure control needed:
   • First choice: Optimize brivaracetam dosing
   • Second choice: Add levetiracetam, lacosamide, or gabapentin (non-aromatic, minimal DRESS association)
   • Absolutely avoid: Perampanel, aromatic AEDs, or any drug with documented DRESS risk
4. Monitor closely for DRESS resolution (fever, rash, eosinophilia, organ involvement)
5. Wait ≥6 months before considering any drug with potential cross-reactivity or DRESS association 5

Critical Pitfalls to Avoid

• Do not assume perampanel is "safe" because it's newer or non-aromatic—the FDA label explicitly warns of DRESS 1
• Do not introduce multiple new AEDs simultaneously during suspected DRESS—you lose the ability to identify the culprit if symptoms worsen
• Do not perform drug provocation testing or rechallenge with any suspected DRESS-causing drug until ≥6 months post-reaction and off steroids for ≥1 month 5
• Do not underestimate DRESS mortality—it can be fatal, with overall mortality around 6.9% in pharmacovigilance data 8

Bottom Line

Perampanel is contraindicated as an alternative AED in suspected DRESS because it carries its own FDA-documented risk of causing DRESS syndrome. 1 The patient should remain on brivaracetam (already tolerated, non-aromatic) and if additional seizure control is needed, add a truly low-risk non-aromatic AED like levetiracetam, lacosamide, or gabapentin—never perampanel in this context.